Hypofractionated Radiotherapy in African Cancer Centers.
Africa
cancer
hypofractionation
radiation
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
10
2020
accepted:
30
12
2020
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
epublish
Résumé
In the advent of the coronavirus disease (COVID-19) pandemic, professional societies including the American Society for Radiation Oncology and the National Comprehensive Cancer Network recommended adopting evidence-based hypofractionated radiotherapy (HFRT). HFRT benefits include reduction in the number of clinical visits for each patient, minimizing potential exposure, and reducing stress on the limited workforce, especially in resource-limited settings as in Low-and-Middle-Income Countries (LMICs). Recent studies for LMICs in Africa have also shown that adopting HFRT can lead to significant cost reductions and increased access to radiotherapy. We assessed the readiness of 18 clinics in African LMICs to adopting HFRT. An IRB-approved survey was conducted at 18 RT clinics across 8 African countries. The survey requested information regarding the clinic's existing equipment and human infrastructure and current practices. Amongst the surveyed clinics, all reported to already practicing HFRT, but only 44% of participating clinics reported adopting HFRT as a common practice. Additionally, most participating clinical staff reported to have received formal training appropriate for their role. However, the survey data on treatment planning and other experience with contouring highlighted need for additional training for radiation oncologists. Although the surveyed clinics in African LMICs are familiar with HFRT, there is need for additional investment in infrastructure and training as well as better education of oncology leaders on the benefits of increased adoption of evidence-based HFRT during and beyond the COVID-19 era.
Identifiants
pubmed: 33680940
doi: 10.3389/fonc.2020.618641
pmc: PMC7933544
doi:
Types de publication
Journal Article
Langues
eng
Pagination
618641Subventions
Organisme : NCI NIH HHS
ID : R01 CA239042
Pays : United States
Informations de copyright
Copyright © 2021 Swanson, Kamwa, Samba, Ige, Lasebikan, Mallum, Ngoma, Sajo, Elzawawy, Incrocci and Ngwa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JCO Glob Oncol. 2020 Apr;6:667-678
pubmed: 32343628
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):440-9
pubmed: 26867873
J Clin Oncol. 2014 Sep 10;32(26):2894-901
pubmed: 25113764
J Clin Invest. 2020 Jun 1;130(6):2741-2744
pubmed: 32224550
Breast Cancer Res Treat. 2020 Jun;181(3):487-497
pubmed: 32333293
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Lancet Oncol. 2020 May;21(5):621-622
pubmed: 32251623
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Adv Radiat Oncol. 2020 Apr 01;5(4):582-588
pubmed: 32292842
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Int J Cancer. 2015 Jun 15;136(12):2875-9
pubmed: 25408458
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116